ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 2849

    Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
  • Abstract Number: 2850

    Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
  • Abstract Number: 2851

    Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
  • Abstract Number: 2852

    Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
  • Abstract Number: 2853

    The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound
  • Abstract Number: 2854

    Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort
  • Abstract Number: 2855

    Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program
  • Abstract Number: 2856

    Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
  • Abstract Number: 2857

    Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
  • Abstract Number: 2858

    The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
  • Abstract Number: 2859

    Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
  • Abstract Number: 2860

    Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
  • Abstract Number: 2861

    Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
  • Abstract Number: 2862

    Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
  • Abstract Number: 2863

    Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
  • « Previous Page
  • 1
  • …
  • 191
  • 192
  • 193
  • 194
  • 195
  • …
  • 198
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology